Flora Peyvandi on Caplacizumab: Which VWF Assays Truly Measure Treatment Effectiveness?
Flora Peyvandi, Professor of Internal Medicine-Hemostasis and Thrombosis Unit, University of Milan, former President of ISTH, shared on X:
“The VWF : GPIbM and VWF:RCo appear the most suitable assays for monitoring VWF activity in iTTP patients treatment with caplacizumab. The VWF:GPIbR have a limited ability to detect caplacizumab’s inhibition. The VWF:Ab assay is unsuitable for this purpose ”
Title: Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor-platelet interaction.
Authors: Paola Colpani, Luciano Baronciani, Ilaria Mancini, Cristina Novembrino, Anna Lecchi, Giovanna Cozzi, Pasqualina De Leo, Massimo Boscolo Anzoletti, Silvia La Marca, Marco Boscarino, Maria Teresa Pagliari, Andrea Artoni, Flora Peyvandi
Read the full article here.
Stay updated with Hemostasis Today.
-
Sep 11, 2026, 17:41Khaled Musallam: Earlier Recognition, Better Outcomes in NTDT
-
Sep 11, 2026, 17:29Reyhan Kose Cobanoglu: APS ACTION Registry Study Published in Lupus
-
Sep 11, 2026, 17:14Obi Light Ogbonnia: From Kenya to Global Sickle Cell Advocacy
-
Sep 11, 2026, 17:01EAHAD 2027 Marks 20 Years
-
Sep 11, 2026, 16:54Denise Braendgaard: Reimagining Health Systems Through Collective Action
-
Sep 11, 2026, 16:47Jehad Khamaysa: Budd-Chiari Syndrome as the Initial Presentation of Behçet’s Disease in a 16-Year-Old
-
Sep 11, 2026, 16:44Mostafa Faisal Mohammed Saleh: From HLA Biology to Curative Therapy
-
Sep 11, 2026, 16:38Jim Kaveney: Class I, Level A – Lifestyle is Now the Official Standard in AFib Care
-
Sep 11, 2026, 16:31George Touma: Do We Really Need to Implant Metal in Every High-Bleeding-Risk Patient?